Pironetin reacts covalently with cysteine-316 of α-tubulin to destabilize microtubule by Yang, Jianhong et al.
ARTICLE
Received 24 Dec 2015 | Accepted 27 May 2016 | Published 30 Jun 2016
Pironetin reacts covalently with cysteine-316
of a-tubulin to destabilize microtubule
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Molecules that alter the normal dynamics of microtubule assembly and disassembly include
many anticancer drugs in clinical use. So far all such therapeutics target b-tubulin, and
structural biology has explained the basis of their action and permitted design of new drugs.
However, by shifting the proﬁle of b-tubulin isoforms, cancer cells become resistant to
treatment. Compounds that bind to a-tubulin are less well characterized and unexploited. The
natural product pironetin is known to bind to a-tubulin and is a potent inhibitor of microtubule
polymerization. Previous reports had identiﬁed that pironetin reacts with lysine-352 residue
however analogues designed on this model had much lower potency, which was difﬁcult to
explain, hindering further development. We report crystallographic and mass spectrometric
data that reveal that pironetin forms a covalent bond to cysteine-316 in a-tubulin via a
Michael addition reaction. These data provide a basis for the rational design of a-tubulin
targeting chemotherapeutics.
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M
icrotubules act as the ‘skeleton of the cell’, as well as
guides and anchors for many cell events. The
a, b-tubulin heterodimer reversibly assembles into
protoﬁlaments of microtubules (Supplementary Fig. 1a). Changes
in this highly dynamic process are tightly controlled and
associated with different stages of the cell cycle and replication1.
The natural products vinblastine, colchicine, taxol, laulimalide
and maytansine all bind to b-tubulin and interfere with the
normal dynamic processes of tubulin: vinblastine, colchicine and
maytansine inhibit polymerization of the tubulin heterodimer
into microtubules2,3 while taxol and laulimalide promote
polymerization and stabilize microtubules2,4. Structural biology
has described in detail how these ﬁve natural compounds bind to
and change the conformation of b-tubulin altering the dynamics
between tubulins and microtubules5–11 (Supplementary Fig. 1b–
e). The work has enabled the rational design of new generation of
analogues with desirable properties although none are as yet in
clinical use12–14. Taxol represents one of the most successful
anticancer agents in current clinic use2,4. However, in patients
undergoing therapy, the increased expression of b-tubulin
isoforms is well known. These isoforms bind less strongly to
taxol, resulting in drug-resistant cancers2,4,15.
Pironetin, an a/b unsaturated lactone originally isolated from
fermentation broths of Streptomyces species, remains the only
natural compound currently known to bind to a-tubulin16
(Fig. 1). Pironetin is a potent inhibitor of the cell cycle halting
cells at M phase (IC50 in the range of 1.5–26 nM (refs 17,18)) and
at a dose of 6.3mg kg 1 intravenous injection inhibits tumour
growth in a mouse model of leukaemia16,19. Importantly,
pironetin was found to be effective against cell lines resistant to
other microtubule-targeted drugs and multidrug-resistant cells
with mdr1 gene expression20. In vitro and in vivo studies showed
the compound acts by inhibiting the polymerization of tubulin
and preventing assembly of the mitotic spindle21. The inhibition
was discovered to be essentially irreversible under physiological
conditions and this led to the prediction that the compound is a
covalent modiﬁer22. A detailed study involving site-directed
mutagenesis, peptide sequencing, in part use of a biotinylated
analogue of pironetin (Supplementary Fig. 2), cell biology and
molecular modelling concluded that pironetin was covalently
attached to Lys352 of a-tubulin22. The study explicitly ruled out
pironetin binding to cysteine residues although from simple
chemical consideration the more nucleophilic cysteine would be
expected to be more reactive in a Michael-type addition to the
lactone (nucleophilic addition to a/b unsaturated carbonyl)
(Fig. 1). This study has formed the basis for the rational
structure-based design of pironetin analogues23. Disappointingly,
the pironetin analogues designed and synthesized on the Lys352
model showed much worse activity (often 1,000-fold worse) than
the parent pironetin24,25. Further, rationalizing the structure–
activity relationships of these compounds has not proven
straightforward, which complicates design of a new generation
of analogues19,21,26. The development of pironetin-based
compounds as novel anticancer agents has stalled.
The attraction of an a-tubulin-binding microtubule-modifying
agent is however very strong. A drug based on such a compound
would almost certainly be insensitive to changes in expression of
b-tubulin isoforms and therefore could help treat drug-resistant
tumours. To provide a ﬁrmer basis for development of novel
analogues, we have reinvestigated the molecular basis of pironetin
activity. Our results do not support the previously published
model of pironetin binding22. Rather structural biology and mass
spectrometry studies using authentic pironetin (not the
biotinylated analogue used previously22) show that pironetin is
covalently bound by Cys316 of a-tubulin where it makes an
extensive set of speciﬁc interactions with the protein. The data
suggest a rational for the molecular basis of inhibition of
microtubule polymerization and explain the failure of previously
synthesized analogues of pironetin to improve potency. The new
model for pironetin binding by a-tubulin enables the rational
design of analogues directed to the creation of a new generation
of anticancer drugs.
Results
Pironetin complex. Crystals of the a, b-tubulin heterodimer
(T2), the stathmin-like protein RB3 (R) and tubulin tyrosine
ligase (TTL) were prepared following published procedures9. This
protein complex, denoted T2R-TTL, has been used in previous
structural studies of tubulin-modifying agents. Its advantage is
that it contains two heterodimers of tubulin and is thus a mimic
for the biological polymer whilst being tractable in terms of
solubility and structural rigidity7,8. We determined the structure
of an apo (no ligand soaked) T2R-TTL complex crystal to 2.2-Å
resolution to provide structure grown under identical conditions
for comparison with the pironetin complex we obtained. The apo
T2R-TTL complex is essentially identical to that previously
described9–11, brieﬂy two a, b-tubulin dimers are arranged as
head to tail (denoted a1b1–a2b2; subunits A, B, C and D,
respectively) with the long a-helix of the stathmin-like peptide
(subunit E) contacting both tubulin dimers. TTL (subunit F)
docks onto a1-tubulin (subunit A). Crystals soaked for longer
O
O
SH
O1 HO H3CO
O
23
4
5
6
7
8 9 10
11
12
13
14
15
16
17
18 19
α
β
O
O–
S
α
β
O
O–
S
α
β
HB+ O
O
S
α
β
B
Figure 1 | Chemical structure of pironetin and the reaction scheme with cysteine. Cysteine as a thiol nucleophile undergoes a Michael-type addition to
pironetin, in which a protonated base (denoted as Bþ ) or solvent accepts the electron from enolate intermediate.
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than 16 h within 0.5mM pironetin visibly deteriorated, gave rise
to irregular diffraction spots with poor diffraction data at
resolutions lower than 5Å. Over 20 crystals soaked with
pironetin for times ranging from 1 to 24 h were screened and
one crystal soaked for 3 h gave high-quality data that we were able
to process to a resolution of 2.6 Å (Table 1). The structures of apo
T2R-TTL complex and T2R-TTL-pironetin complex are
essentially identical. The two a-tubulin subunits (A and C)
clearly have GTP bound. In b2-tubulin (subunit D) of both
structures, the density is better ﬁtted with GTP than GDP. In
b1-tubulin (subunit B) of both structures, the density is more
consistent with GDP but not unambiguously so (Supplementary
Fig. 3). This nucleotide pattern has been previously reported27.
Comparison of the residues that surround the nucleotide-binding
site (by superposition) shows no difference between the subunits
B and D in both structures. Thus, in our crystals either both B
subunits do contain GTP or the change from GTP to GDP has
occurred in the B subunit without any change in protein
structure.
The Fo–Fc difference electron density of the soaked crystals
unambiguously identiﬁes a covalent adduct at Cys316 of
a2-tubulin (subunit C)(Fig. 2a). No additional clear density was
identiﬁed around any other residue; we were particularly careful
to check Lys352 (Fig. 2a and Supplementary Fig. 4). Pironetin was
built into the positive Fo–Fc density with a good ﬁt (Fig. 2a). The
molecule was reﬁned as a thiol Michael adduct using a dictionary
from PRODRG server28. The binding site is entirely contained
within a2-tubulin subunit (Fig. 2b). We did not model a second
pironetin at Cys316 of a1-tubulin subunit, although we observed
additional weak Fo–Fc density there. Cys316 is found on b-strand
S8 (we have followed the published nomenclature of tubulin
secondary structure elements6) and the pironetin molecule adopts
an extended conformation that is perpendicular to the antiparallel
b-sheet (strands S7, S8, S9 and S10) (Fig. 2c). The lactone ring of
pironetin sits in a pocket formed by the residues from the
antiparallel b-sheet (Fig. 2c,d). The ring and its ethyl substituent
make van der Waal contacts with Leu378 and the main chain
around Cys316. The hydroxyl alkyl chain extends into a channel
that is formed by the helices H7, H8, b-strand S5 and loop T7
that connects H7 to H8 (Fig. 2c,d). The side chain of Phe255
(H8), Leu242 (H7) and Leu167 (S5) in particular makes van der
Waal contacts with the chain (Fig. 2c). The terminal methyl
group of pironetin sits in a large pocket formed by b-strands S1,
S4 and S5 (part of another parallel b-sheet) and makes van der
Waal contacts with Cys4, Gly134 and Leu167 (Fig. 2c,d).
Mass spectrometry. We incubated a, b-tubulin with pironetin at
a molar ratios of 1.1:1 and 1:20 (protein:pironetin) for 3 h at
20 C. The reactions were quenched by addition of free cysteine,
and the protein was separated on SDS–polyacrylamide gel elec-
trophoresis (SDS–PAGE). The bands corresponding to a and b-
tubulin were excised, subjected to reduction, alkylation and in-gel
digestion with trypsin followed by analysis with nLC-ESI MS/MS.
Under both treatments (1.1:1 and 1:20) we observed the pironetin
covalently modiﬁed peptide (312-YMACCLLYR-320). Fragmen-
tation of this peptide shows that pironetin is attached to Cys316
but not to Cys315. Detailed inspection of the MS/MS fragmen-
tation pattern showed all the y ions containing Cys316 displayed
diagnostic loses of 32 and 50Da from pironetin (Fig. 3).
No pironetin binding was detected in observed peptides that
contained Cys200, 213, 295, 347 and 376. Peptides containing
Cys4, 20, 25, 129 and 305 were not observed so modiﬁcation of
these cannot be deﬁnitively excluded by mass spectrometry but
clearly not any modiﬁcation was found on those Cys residues in
crystal structure (Supplementary Fig. 4). In the untreated protein
Table 1 | Data collection and reﬁnement statistics.
Apo T2R-TTL (5JQG) T2R-TTL-pironetin (5FNV)
Data collection
Space group P212121 P212121
Cell dimensions
a, b, c (Å) 105.05, 158.12, 180.63 106.16, 157.20, 181.68
a, b, g () 90, 90, 90 90, 90, 90
Resolution (Å) 35.22–2.24 (2.30–2.24) 45.5–2.61 (2.68–2.61)*
Rmerge 0.074 (0.574) 0.058 (0.491)
I/sI 14.9 (2.8) 15.8 (1.6)
Completeness (%) 100 (99.9) 94.8 (67.5)
Redundancy 6.7 (6.3) 5.3 (2.5)
CC (1/2) 0.998 (0.846) 0.999 (0.652)
Reﬁnement
Resolution (Å) 35.22–2.24 41.76–2.61
No. of reﬂections 144,634 87,988
Rwork/Rfree 0.181/0.212 0.186/0.226
No. of atoms 17,646 17,276
Protein 17,126 16,999
Ligand/ion 187 209
Water 333 68
B-factors 49.4 80.5
Protein 49.7 80.7
Ligand/ion 43.5 69.8
Water 39.3 54.8
R.m.s. deviations
Bond lengths (Å) 0.015 0.012
Bond angles () 1.68 1.64
R.m.s., root mean squared.
The resolution limits were determined by half-data set correlation (CC (1/2))42 and values in parentheses are for highest-resolution shell.
*One crystal was used for data collection and structure determination.
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we observed the 340-TIQFVDWCPTGFK-352 peptide. We were
also able to see this (unmodiﬁed) peptide in the 20:1 pironetin-
treated protein (Supplementary Fig. 5). Further, were the protein
modiﬁed, the lysine would no longer be a trypsin cleavage site
giving rise to the modiﬁed peptide 340-TIQFVDWCPTGFKV-
GINYEPPTVVPGGDLAK-370. We performed a product ion
scan to speciﬁcally isolate the predicted m/z for this adduct but no
signal was found.
Structural changes on pironetin binding. At a gross level, the
binding of pironetin to a2-tubulin subunit has resulted in a 2
rotation (2.2 between our structures and 1.9 when compared
with the existing apo structure (PDB code: 4I55)) in the relative
positions of the a1b1 heterodimer with respect to the a2b2
heterodimer (Fig. 4a). At the secondary structural level there is a
pronounced shift in the position of loop T7 (residues Phe244 to
Leu259): the Ca atom of Val250 has moved over 11Å, whilst
Leu252 has shifted over 6Å and Gly246 by 8Å (Fig. 4b). The
movement is a direct consequence of pironetin binding, as in the
apo structure this part of the T7 loop occupies the same volume
as the pironetin hydroxyl alkyl chain. In the complex, the T7 loop
is stabilized by a contact consistent with a salt bridge between
Asp251 (from a2-tubulin, subunit C) and Lys103 (from
b1-tubulin, subunit B; Fig. 4b). There are further interactions
consistent with hydrogen bond interactions between the amides
of Val250 in a2-tubulin with the side chain of Glu69 from
b1-tubulin (Fig. 4b). The residues on either side of Cys316 on
strand S8 undergo small shifts with different side chain
conformers for both Cys316 and Leu318 that are required for
pironetin binding (Fig. 4c). In addition, there are small changes in
the positions of atoms on the neighbouring strands.
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Figure 2 | Structure of the tubulin-RB3-TTL-pironetin complex. (a) Stereo views of experimental Fo–Fc difference electron density contoured at 3s in
green for pironetin and the side chains of C316 and K352 and the ﬁnal reﬁned 2Fo–Fc electron density contoured at 1s in blue. The ﬁnal reﬁned positions of
pironetin, C316 and K352 are shown in stick with carbons coloured cyan for pironetin and green for protein, oxygens red and nitrogens blue. (b) Structure of
tubulin-RB3-TTL in complex with pironetin in which pironetin is bound to a2-tubulin. The protein subunits are shown in cartoon. The ligands are shown as
spheres with atoms coloured as in a. (c) Close-up view of pironetin in the pocket of a-tubulin monomer. (d) Cross-section view of the surface of the binding
pocket of pironetin. K352 previously reported to be modiﬁed is shown alongside other residues discussed in the text.
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There is also a shift in the position of the N-terminal end of
helix H8 that correlates with the changes in the T7 loop, notably
the side chain of Phe255 has undergone a large re-orientation
(Fig. 4c). Glu254 is a key catalytic residue that in the apo structure
binds to water molecules that in turn binding to a Mg2þ ion of
the neighbouring b1-tubulin (Fig. 4c). The Mg2þ ion is in
contact with a-phosphate of GDP. However, Glu254 in this
complex lacks the link to Mg2þ due to a movement of 4 Å of the
carboxylate group. Glu254 has been proposed to enhance the
tubulin GTPase activity29,30. The distortion of the precise
position of Glu254 and the resulting lower catalytic capacity for
GTPase activity of b-tubulin (Fig. 4d) may be an additional
mechanism of pironetin to destabilize the assembly of tubulin
into microtubules.
Notably, the changes in the structure of a-tubulin are focused
at the inter-dimer interface between a2-tubulin (subunit C) and
b1-tubulin (subunit B). It is this interface between heterodimers
that directly and exquisitely controls tubulin polymerization7,8,10.
Electron micrographs and sedimentation analysis were used to
conﬁrm that the tubulin and pironetin used in this study showed
the expected disruption of microtubule formation
(Supplementary Fig. 6). Controls of tubulin treatment with
colchicine and vinblastine gave the expected results8,31
(Supplementary Fig. 6). We take these results to conﬁrm the
authenticity of both the protein and the compound used.
Discussion
Mass spectrometric and crystallographic data establish that
pironetin binds covalently to Cys316 of a-tubulin. The mass
spectrometric analysis was carried out on tubulin heterodimer in
solution (without the other proteins used to obtain crystals) to
ensure the modiﬁcation of Cys316 was not the result of crystal
packing or an artefact of T2R-TTL protein complex used. Both
techniques identify that pironetin binding is speciﬁc, in that other
cysteines on the surface of the protein, available for reaction, were
not modiﬁed. Unfolding the protein (during mass spectrometric
analysis) in the presence of excess pironetin does result in
additional nonspeciﬁc cysteine modiﬁcation. This indicates that
the speciﬁc Cys316 modiﬁcation seen for the folded protein
requires recognition of pironetin, consistent with the crystal
structure which identiﬁes a binding pocket in the protein.
Chemical considerations suggest that the thiol of cysteine will be a
more potent nucleophile than amine of lysine for Michael
addition. Thus, cysteine modiﬁcation by the a/b unsaturated
lactone of pironetin might be expected, these results contradict an
earlier study that had reported covalent binding to Lys352 (ref.
22). The identiﬁcation of Lys352 as the target had relied on an Ala
mutational scan of lysine and cysteine residues from Lys280 to
Lys352 following treatment with a biotinylated derivative of
pironetin22. The data showed that the mutations K352A and
N258A caused large reduction of binding of biotin-modiﬁed
pironetin whilst mutations C315A and C316A slowed down but
not reduce the overall amount of binding to the biotinylated
derivative22. Interestingly, this study showed that pironetin
binding could be reversed under relatively mild conditions, at
pHs below 4.5 or above 8.5 (ref. 22). We suggest this observation
is more consistent with a thiol adduct of pironetin rather than the
more chemically stable amine adduct. We examined the residual
density in the crystal structure at Lys352 (Supplementary Fig. 4)
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Figure 3 | MS/MS fragmentation pattern for pironetin covalently modiﬁed peptide from a-tubulin .The spectrum clearly shows the covalent binding of
pironetin to C316 rather than the adjacent C315, which was modiﬁed by carbamidomethyl (marked by *). The pironetin containing fragments show
characteristic loses of 32 and 50m/z. Prec denotes precursor ion.
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but see no density for any modiﬁcation. Mass spectrometry of the
pironetin-treated protein shows no evidence for any modiﬁcation
on Lys352. In fact, mass spectrometry detects the unmodifed
Lys352 ((Supplementary Fig. 5) even after treatment of the
protein with high ratio of pironetin, this is positive evidence that
Lys352 is not labelled by native pironetin.
The structure of tubulin complexed to pironetin shows that the
binding pocket is entirely contained in a-tubulin subunit close to
the interface between different tubulin heterodimers (such as
a2-tubulin and b1-tubulin subunit). This pocket absent in the
apo structure and is created by an induced-ﬁt mechanism with a
large re-orientation of T7 loop. Such induced-ﬁt binding sites are
rarely predicted by modelling highlighting the importance of
experimental structural study. The previous study had used
biotinylated pironetin (Supplementary Fig. 2), and we note the
pocket seen here could not accommodate biotinylated pironetin
as the biotin component would clash with Phe255 and other
residues in the pocket. As we are unable to synthesize or source
the biotinylated analogue of pironetin, we have not been to
investigate the behaviour of the biotinylated pironetin using our
analytical approaches.
The disappointing results from the design and synthesis of
pironetin analogues24,25 can now be rationalized in light of the
new structural data. The loss of the ethyl substituent on the
lactone ring disrupts the hydrophobic interactions with Leu378
and would create an unfavourable void. The most potent
analogue of pironetin preserved this group but missed two
methyl substituents from the alkyl chain. These methyl groups do
not make direct interactions but favour the extended
conformation of pironetin and this, we suggest, is critical in
inducing the interaction between Phe255 and the drug.
In the crystal structure, pironetin is modelled bound to one of
two a-tubulin molecules (a2-tubulin, subunit C), there is only
weak density for the molecule in a1-tubulin (subunit A) and
disordering of some neighbouring residues. We suggest the
reason for this asymmetric binding of pironetin is that the
stathmin-like peptide RB3, necessary for crystallization of the
complex, has extensive interactions with strand S9 as well as loop
T7 of a-tubulin. We hypothesize that modiﬁcation of the
a1-tubulin subunit (subunit A) would disrupt RB3-(a-tubulin)
interactions and thus crystal packing, consistent with the poor
quality of diffraction for those crystals with prolonged soaking
times.
Since pironetin perturbs the longitudinal contacts between the
tubulin heterodimers, we suggest that this is the basis by which it
promotes the disassembly of microtubules (Fig. 5). The vinca
class of alkaloids, such as vinblastine, bind to a site on b-tubulin,
which is also at the interface between heterodimers and act by
perturbing the polymerization8. Interestingly, vinblastine in the
crystal structure of its complex with tubulin results in a change in
the position of the key catalytic Glu254 of a-tubulin8, the same
residue undergoes a shift, but a different one, in the pironetin
complex. This overlap in structural effects may underpin the
observed competition between vinblastine and pironetin21.
Colchicine binds to b-tubulin at intra-dimer interface (the
opposite end of b-tubulin than the vinca alkaloids)7 also
inhibits polymerization. Taxol in contrast, binds at a third site
in the middle of b-tubulin and stabilizes the ﬂexible M loop
promoting stabilization of microtubules6,9.
Pironetin has been shown to possess antitumour activity and is
the only known compound that modiﬁes microtubule assembly
by covalent modiﬁcation of a-tubulin. Thus, pironetin-like
compounds have attractive potential as treatments of tumours
in which switch in the isoform of b-tubulin has rendered the
cancer resistant to b-tubulin-binding drugs, including taxol. The
covalent attachment of pironetin to tubulin all but eliminates
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Figure 4 | Changes in a-tubulin on pironetin binding. (a) Comparison of the structures of tubulins in apo form and in complex with pironetin. The tubulin
dimers are represented as ribbons. In apo form, a-tubulin is coloured blue and b-tubulin light grey. In the complex with pironetin, a is green and b dark grey.
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observed with vinblastine and opposite to the stimulation seen with colchicine.
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the vulnerability to efﬂux pumps. The complex structure of
pironetin and tubulin reveals a previously unknown but highly
speciﬁc ligand binding site. Exploitation of this binding site can
be now be used to create a new class of anti-cancer compounds
targeting a-tubulin.
Methods
Materials. Clones of stathmin-like domain of RB3 (RB3-SLD) and TTL were
obtained as kind gifts from Dr Benoıˆt Gigant (CNRS, France) and Dr Michel O.
Steinmetz (PSI, Switzerland). Pironetin was purchased from Biomol or Oskar
Tropitzsch; colchicine, Bis Tris Propane, tyrosine, AMPPCP (adenylylmethylenedi-
phosphonate or b, g-methyleneadenosine 50-triphosphate) and DTT (dithiothreitol)
from Sigma-Aldrich and vinblastine from Selleck. Other frequently used reagents
were purchased from Sigma-Aldrich or similar quality suppliers. A single batch of
porcine brain tubulin (499% pure, Catalogue No: T238P) was sourced from
Cytoskeleton Inc., snap frozen immediately on delivery into 10mgml 1 aliquots
and stored at –70 C until required.
Methods. Protein expression and puriﬁcation. On the basis of a published pro-
cedure9, RB3-SLD was expressed in and puriﬁed by anion-exchange
chromatography from Escherichia coli, followed by a ﬁnal step of gel ﬁltration in
10mM HEPES-NaOH buffer (pH 7.2), 150mM NaCl and 2mM DTT. Pure RB3-
SLD protein was concentrated to 10mgml 1 and stored at  80 C. His-tagged
TTL was puriﬁed from E. coli by Ni2þ afﬁnity chromatography, followed by gel
ﬁltration in 20mM Bis Tris Propane buffer (pH 6.5), 200mM NaCl, 2.5mM
MgCl2, 5mM b-mercaptoethanol, 1% glycerol and ﬁnally concentrated to
20mgml 1 and stored at  80 C. The purity of RB3 and TTL were assessed by
SDS–PAGE. Porcine brain tubulin was purchased and supplied at 10mgml 1 in
GTB buffer (general tubulin buffer: 80mM PIPES (pH 6.9); 2mM MgCl2; 0.5mM
EGTA; and 1mM GTP) and preserved at  80 C until use.
Structural biology. A protein solution consist of tubulin (10mgml 1), TTL
(20mgml 1) and RB3 (10mgml 1), with molar ratios of each component at
2:1.3:1.2 (Tubulin:RB3:TTL), was incubated on ice. To this was added 1mM
AMPPCP, 5mM tyrosine and 10mM DTT, and the resulting mixture concentrated
to 20mgml 1 at 4 C. Sitting-drop crystallization drops contained 1 ml protein
solution and 1 ml of 6% PEG 4000, 5% glycerol, 0.1M MES, 30mM CaCl2 and
30mM MgCl2, pH 6.7 at 20 C. Crystal growth was accelerated by seeding27, and
crystals appeared after incubation at 20 C in the same day and reached a length of
200–300 mm within 3–5 days.
A volume of 0.1 ml of pironetin, dissolved in dimethylsulphoxide at 10mM
concentration, was added to a sitting drop containing crystals at 20 C. The time
for soaking was varied between 1 and 24 h, with the crystals examined for visibly
cracking or degradation. Crystals (both native and soaked) were removed from the
drop on a loop dipped into cryoprotectant (8% PEG 4000, 30mM MgCl2, 30mM
CaCl2, 0.1M MES, pH6.7 and 20% glycerol) before being ﬂash-cooled in liquid
nitrogen.
X-ray diffraction data were collected at beamline BL19U1 at Shanghai
Synchrotron Radiation Facility (SSRF, National Center for Protein Science
Shanghai, Institute of Biochemistry and Cell Biology, Chinese Academy of
Sciences, P. R. China) using the MX225 CCD (charge-coupled device) detector at a
wavelength of 0.97853Å. Data were indexed, integrated and scaled using Xia2
package32–35. The structures were solved by the molecular replacement method,
with an existing apo structure T2R-TTL (no soaking ligands) (PDB code: 4I55) as
the search model by using Phaser36. Manual model building and following
reﬁnement were done by using Coot37 and Refmac5 (ref. 38). The restraint library
for pironetin was produced from PRODRG server28. The ﬁnal data collection and
reﬁnement statistics are summarized in Table 1.
Mass spectrometry. We incubated 20ml a, b-tubulin at 27mM concentration
with inadequate and excessive pironetin at a molar ratios of 1.1:1 and 1:20
(protein:pironetin) at 20 C for 3 h quenched by free amino acid cysteine and then
ran the reactions on SDS–PAGE. The excess free amino acid cysteine is crucial to
mask the residual pironetin in the sample before denaturing tubulin for SDS–
PAGE. If excess pironetin was not quenched before unfolding on SDS–PAGE,
additional cysteine residues (but not lysine) were modiﬁed. The gel band was
excised and cut into 1-mm cubes. These were then subjected to in-gel digestion,
using a ProGest Investigator in-gel digestion robot (Genomic Solutions) following
the standard protocols39. Brieﬂy the gel cubes were destained by washing with
acetonitrile and subjected to reduction, with dithiothreitol, and alkylation, with
iodoacetamide, before digestion with trypsin at 37 C in 25mM ammonium
bicarbonate buffer. The peptides were extracted with 5% formic acid and
concentrated down to 20 ml using a SpeedVac (Thermo Savant).
The peptides were then separated on an Acclaim PepMap 100 C18 trap and an
Acclaim PepMap RSLC C18 column (Thermo Fisher Scientiﬁc), using a nanoLC
Ultra 2D plus loading pump and nanoLC as-2 autosampler (Eksigent). The
peptides were eluted with a gradient of increasing acetonitrile, containing 0.1%
formic acid (5–40% acetonitrile in 16min, 40–95% in a further 1min, followed by
95% acetonitrile to clean the column, before re-equilibration to 5% acetonitrile).
The eluant was sprayed into a Triple TOF 5600þ electrospray tandem mass
spectrometer (Sciex) and analysed in information-dependent acquisition mode,
performing cycles of 250ms of MS followed by 100ms MS/MS analyses on the 15
most intense peaks seen by MS.
The MS/MS data ﬁle generated via the ‘Create mgf ﬁle’ script in PeakView
(Sciex) was analysed using the Mascot algorithm (Matrix Science), against an in-
house database to which a-tubulin subunit sequence had been added, with trypsin
as the cleavage enzyme and carbamidomethyl modiﬁcation of cysteines, pironetin
modiﬁcation of cysteines, pironetin modiﬁcation of lysines, methionine oxidation
and deamidation of glutamines and asparagines as a variable modiﬁcations.
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Figure 5 | The molecular mechanism of pironetin and other tubulin-targeting agents to alter the tubulin-microtubule dynamics. The tubulin-targeting
agents colchicine, vinblastine and taxol are shown. This ﬁgure is inspired by a previous publication10 but designed and developed with the data in this study.
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A repeat injection was made using the same HPLC conditions with the mass
spectrometer operating in product ion scan mode to speciﬁcally isolate and
characterize the m/z’s for fragmentation of 312-YMACCLLYR-320 and 340-TIQ
FVDWCPTGFKVGINYEPPTVVPGGDLAK-370 with pironetin adducts and
carbamidomethyl adducts covalently bound.
Transmission electron microscopy. Tubulin (10 mM) solution was prepared in
GTB-glycerol buffer (80mM PIPES buffer (pH 6.9), 2mM MgCl2, 0.5mM EGTA,
1mM GTP and 10% glycerol) at 4 C. Tubulin in this buffer does not assemble at
4 C but will assemble spontaneously at 37 C. Different microtubule-destabilizing
agents colchicine, vinblastine and pironetin were added to tubulin at 10 mM and
incubated at 37 C for 30min, respectively. A volume of 5 ml of sample was added
to a 230-mesh per inch formvar, supported by carbon ﬁlms, adsorbed for 2min,
washed twice with water and negatively stained for 60 s with 2% (w/v)
phosphotungstic acid. A FEI T12 transmission electron microscope was used for
observation at 80 Kv, and the pictures were recorded into a Serial EM software by a
2k 2k Gatan CCD camera
Tubulin sedimentation analysis. Tubulin (20 mM) solution was prepared in
GTB-glycerol buffer. Different microtubule-destabilizing agents at indicated
concentrations were added to the tubulin and incubated at 37 C for 30min.
Ultracentrifugation (250,000g, 15min) was performed to separate the pellets
(aggregates of tubulin) and supernatants (tubulin), which were both subjected to
SDS–PAGE, respectively, and stained by Coomassie brilliant blue.
GTPase assay. Analysis of tubulin GTPase activity was performed using the
QuantiChromTM ATPase/GTPase Kit (DATG-200) from BioAssay Systems
following the manufacturer’s instruction and the published GTPase assay of
tubulin40,41. The ﬁnal volume of the GTPase assay is 300ml and is carried out in GTB
buffer with 10mM of the assay compounds (colchicine, vinblastine and pironetin, all
dissolved in dimethylsulphoxide at 0.5mM concentration (50-fold stock solution))
and is initiated by addition of 66ml of tubulin (giving a ﬁnal concentration of tubulin
of 20mM). At different time intervals (0, 15, 30 and 60min), 70ml reaction solution
was removed and rapidly mixed with perchloric acid (ﬁnal concentration of 2.5%) to
stop the reaction. Protein was removed from the reaction by ultraﬁltration. A volume
of 200ml of the developing reagent (supplied in the kit) was added to 40ml reaction
ﬁltrate and incubated for 30min at room temperature. The absorbance at 620nm was
measured by a Spectramax M5 Microtiter Plate Luminometer (Molecular Devices,
USA) and the data were plotted to show the activity change on the microtubule-
destabilizing agents with the phosphate concentration released at 0min as the blank.
Data availability. The coordinates and structure factors that support the ﬁnding of
this study have been deposited in the Protein Data Bank with the accession codes
5JQG and 5FNV, respectively, (http://www.rcsb.org/pdb/home/home.do). Further
data of transmission electron microscopy, tubulin sedimentation analysis and
GTPase assay are available from the corresponding author L.C. (ljchen@scu.edu.cn)
and others are available from X.Z. (zhuxiaofeng@scu.edu.cn) on request.
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